LONDON, UK / ACCESSWIRE / April 29, 2024 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Poolbeg Pharma PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify) iii : 3. Details of person subject to the notification obligation iv Name Michael Kelly City and country of registered office (if applicable) 4. Full name of shareholder(s) (if different from 3.) v Name City and country of registered office (if applicable) 5. Date on which the threshold was crossed or reached vi : 15 TH March 2024 6. Date on which issuer notified (DD/MM/YYYY): 26 th April 2024 7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer vii Resulting situation on the date on which threshold was crossed or reached 4.8% 4.8% 23,988,955
Position of previous notification (if
applicable) 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares
Class/type of shares
ISIN code (if possible) Number of voting rights ix % of voting rights Direct (DTR5.1) Indirect (DTR5.2.1) Direct (DTR5.1) Indirect (DTR5.2.1) GB00BKPG7Z60 23,988,955 4.8% SUBTOTAL 8. A 23,988,955 4.8% B 1: Financial Instruments according to DTR5.3.1R (1) (a) Type of financial instrument Expiration date x Exercise/ Conversion Period xi
Number of voting rights that may be acquired if the instrument is
exercised/converted. % of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) Type of financial instrument Expiration date x Exercise/ Conversion Period xi
Physical or cash
settlement xii Number of voting rights % of voting rights SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary) X Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold Michael Kelly 10. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11. Additional information xvi Place of completion Dublin, Ireland Date of completion 26 th April 2024
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com .
SOURCE: Poolbeg Pharma PLC View the original press release on accesswire.com
|
